219 results about "Zika virus" patented technology

The invention discloses a monoclonal antibody of Japanese encephalitis virus and Zika virus and application of the monoclonal antibody, and relates to the technical field of immunology and molecular virology. The monoclonal antibody or the antigen binding fragment thereof comprises a VH CDR1, a VH CDR2 and a VH CDR3 of which the amino acid sequences are as shown in SEQ ID NO: 1-3, and a VL CDR1, a VL CDR2 and a VL CDR3 of which the amino acid sequences are as shown in SEQ ID NO: 4-6. A large number of experimental studies show that the monoclonal antibody can specifically recognize and target extracellular regions of E proteins of the Japanese encephalitis virus and the Zika virus, can block combination of the E proteins and cell surface receptors, and shows efficient virus neutralizing capacity. Therefore, the antibody provided by the invention is particularly suitable for being used for diagnosing, preventing and / or treating diseases related to Japanese encephalitis virus and Zika virus infection.

The invention discloses a novel application of an RNF6 gene, namely, an application of screening a medicine for preventing and / or treating Zika virus infection, aiming at inhibiting expression of the RNF6 gene or knocking out the RNF6 gene. A series of functional experiments prove that the RNF6 gene promotes the replication of the Zika virus, and the purpose of reducing the replication of the Zika virus can be achieved by using an expression inhibitor of the RNF6 gene or knocking out the RNF6 gene; experimental results show that the RNF6 gene can be used as a potential target for preventing and / or treating Zika virus infection, and a new direction is provided for development of drugs for preventing and / or treating Zika virus infection targeting the RNF6 gene in the future.

The present disclosure relates to field of lyophilized / freeze-dried viral vaccine composition and methods for manufacturing and obtaining the vaccine composition comprising live attenuated flavivirus as vaccine antigen selected from a group of yellow fever virus, dengue virus, Japanese encephalitis (JE) virus, Kunjin virus, West Nile (WN) virus, tick-borne encephalitis (TBE) virus, St. Louis encephalitis virus, Murray Valley encephalitis virus, Zika virus vaccine antigen; and stabilizers comprising sugar or sugar alcohol; amino acids; lactalbumin hydrolysate and gelatin. Post reconstitution, the composition preserves the desired characteristics of the virus, including immunogenicity and stability. The composition of the present disclosure can be safely administered subcutaneously or intramuscularly such that the vaccine composition induces complete immune response to yellow fever virus infectious agent and meets the criterion for the seroprotection for the said immunogenic components comprising yellow fever virus.

The invention provides a multiplex fluorescent quantitative PCR (polymerase chain reaction) detection kit for mosquito-borne viruses and a detection method of the multiplex fluorescent quantitative PCR detection kit. The detection kit comprises multiple PCR reaction liquid, positive quality control and negative control, the multiplex PCR reaction liquid comprises four specific probes and four pairs of specific primers which are respectively used for detecting the dengue fever virus, the Japanese B encephalitis virus, the Zika virus and the west nile virus; the detection method comprises the following steps: extracting a to-be-detected sample, preparing a PCR mixed solution of a to-be-detected drug, performing PCR amplification and reading a fluorescence signal. Through the mode, the dengue virus, the Japanese B encephalitis virus, the Zika virus and the west nile virus can be specifically recognized, the dengue virus, the Japanese B encephalitis virus, the Zika virus and the west nile virus can be quantitatively detected by combining the standard curve, the detection efficiency is high, the implementation can be stable, the operation is simple, convenient and rapid, and the detection cost is low. The detection speed is high, and the detection accuracy and sensitivity are relatively high.

The invention discloses a primer combination and a kit for detecting arbo viruses and application of the primer combination and the kit. The primer combination comprises a specific primer pair for detecting the dengue virus, a specific primer pair for detecting the Zika virus and a specific primer pair for detecting the Chikungunya virus. The primer combination has the characteristics of high sensitivity, good repeatability and strong specificity, and can be used for specifically detecting dengue virus, Zika virus and Chikungunya virus.

Disclosed herein are nucleic acid compositions for delivering polynucleotides of interest.

The invention belongs to the field of molecular biological detection, and particularly relates to combined nucleic acid detection of three typical mosquito-borne arthroviruses, namely, dengue virus, Zika virus and Chikungunya virus, and four serotypes of the dengue virus are typed by using a melting curve matched molecular beacon design method. The method specifically comprises the following steps: distinguishing and detecting three typical mosquito-borne arbo viruses by using an amplification curve, and marking pathogens in each tube on different probes by using different fluorophores so as to distinguish amplification signals. A melting curve is used for distinguishing four different types of viruses of the dengue virus, and Tm value characteristic peak signals are distinguished by combining a molecular beacon and a locked nucleic acid probe aiming at each type of specific target. According to the invention, clinical differential diagnosis of the three viruses is facilitated, and an auxiliary means is provided for guiding medication for different clinical manifestations in dengue virus typing detection.

The invention belongs to the field of biological medicines, and discloses an application of a VPS35 inhibitor in preparation of Zika virus infection resistant drugs, the VPS35 inhibitor comprises at least one of the following two substances: I: a substance for inhibiting VPS35 gene expression in host cells; and II: a substance for inhibiting the retrograde transport function of the VPS35 protein in the host cell. The invention finds that the VPS35 protein is an important host factor of the replication period of the Zika virus for the first time, and a Zika virus infection model system verifies that the replication of the Zika virus in the host cell can be inhibited by inhibiting the expression of the VPS35 gene in the host cell or inhibiting the retrograde transport function of the VPS35 protein. Compared with traditional drugs targeting Zika virus protein, the VPS35 inhibitor provided by the invention targets host factors, is more difficult to induce Zika virus drug resistance, and has more lasting treatment potential.

The invention provides a joint detection test strip for dengue virus and Zika virus antigens and antibodies and a preparation method of the joint detection test strip. According to the combined detection test strip, the combined detection test strip with the dengue virus NS1 antigen and the dengue virus IgG / IgM antibody adopts a multi-site recombinant antigen labeling or multi-site recombinant antibody coating form, so that the sensitivity of a reagent is improved; the problems of poor specificity and release residue of latex microspheres are solved by optimizing the confining liquid; colored latex microspheres are used as a marker, a detection target is more intuitively distinguished according to line colors, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is more quickly improved, and the dengue virus NS1, the Zika virus NS1 antigen, the dengue virus IgG / IgM antibody and the Zika virus IgG / IgM antibody can be detected at the same time; and the kit is convenient to carry, simple to operate, convenient for on-site instant detection and capable of performing large-scale preliminary screening.

This invention discloses the application of the DNAL1 gene as a target in screening drugs for the prevention and treatment of Zika virus or dengue virus type 2 infection, specifically the application of screening drugs for the prevention and / or treatment of Zika virus or dengue virus type 2 infection with the aim of inhibiting or knocking out the DNAL1 gene. The invention has found that the DNAL1 gene is a key host factor promoting the replication of Zika virus or dengue virus type 2, and that inhibiting the DNAL1 gene through siRNA or knocking out the DNAL1 gene through CRISPR / Cas9 can inhibit the replication of Zika virus or dengue virus type 2. The DNAL1 gene is a potential host factor for flaviviruses, and this invention provides a potential target for the prevention and / or treatment of Zika virus or dengue virus type 2 infection.

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

The invention relates to the technical field of biology, and provides a primer group and a kit for simultaneously detecting a dengue virus and a Zika virus and application of the primer group, and the primer group is formed and comprises a primer pair 1 aiming at the dengue virus, a primer pair 2 aiming at the Zika virus and a universal LAMP (Loop-Mediated Isothermal Amplification) primer pair. When in use, target virus single-stranded RNA is used as a bridge molecule, under the catalysis of Splint R ligase, adjacent DNA probes with specific sequences are guided and connected, and a double-ring (dumbbell-shaped) structure product containing a general cyclization primer sequence is directly formed. The two key technical breakthroughs of forming a universal double-ring primer through target RNA mediated probe connection and outputting a high-specificity signal dependent on RNase H2 are realized; a dengue virus and Zika virus isothermal nucleic acid amplification detection platform which is simple and convenient to operate, rapid in reaction, high in sensitivity, strong in specificity (capable of effectively avoiding interference of primer dimers and non-specific dyes) and suitable for multiple detection is constructed, and compared with conventional fluorescent quantitative PCR, the dengue virus and Zika virus isothermal nucleic acid amplification detection platform has remarkable advantages.

CD24-positive malignant and benign tumors are treated by administration of a naturally occurring or modified oncolytic Zika virus. Diseases associated with abnormal T cell activation or T cell-mediated autoimmunity, wherein CD24 expression is increased, are also expected to be treated by administration of a naturally occurring or modified oncolytic Zika virus. Also contemplated are compounds and methods for treating and / or preventing Zika virus infection in a subject.

This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.

Provided are Zika virus constructs and methods of using Zika virus constructs and Zika viruses to treat subjects in need thereof.

The disclosure provides for recombinantly modified Zika-based vectors that can be used in gene therapy applications.

The invention discloses application of ACSS2 as an action target in screening or preparing a medicine for preventing or treating virus-induced vascular remodeling diseases, and belongs to the field of biological medicine. It is found that by inhibiting ACSS2 gene expression or protein activity, Zika virus induced vascular smooth muscle cell phenotypic transformation can be remarkably reversed, and occurrence and development of angiotensin II / aminopropionitrile induced aortic aneurysm / dissection are relieved. The invention provides a siRNA sequence (SEQ ID NO.1-2) specifically targeting ACSS2 and a pharmaceutical composition containing the siRNA, and provides a novel treatment target and a precise intervention tool for virus-related vascular remodeling diseases.

The present invention relates to a vaccine for the prevention or treatment of a Zika virus infection and / or a Zika virus associated clinical illness of any severity. Further provided are methods for producing and inactivating Zika virus as well as processes for manufacturing compositions comprising Zika virus.

The invention discloses application of a five-membered sulfur-containing heterocyclic nucleoside lead compound in anti-Zika virus active drugs, and belongs to the technical field of medicinal chemistry. A series of five-membered sulfur-containing heterocyclic ring nucleoside compounds are synthesized through a Sulfa-Michael / Aldol cascade reaction or a Michael addition reaction. Results show that in an anti-Zika virus test, the five-membered sulfur-containing heterocyclic nucleoside lead compounds 39b, 22r and 22n have relatively good anti-Zika virus activity, and a new structural unit is provided for anti-virus candidate drug molecules.

The present disclosure relates to vaccines and immunogenic compositions comprising an antigen from a Zika virus (e.g., wherein the antigen is an inactivated whole Zika virus), and their use in medical applications (such as methods of treatment).

The invention relates to recombinant polynucleotides encoding at least a recombinant polynucleotide expressing at least a first fusion polypeptide that comprises MHC class I T-cell epitopes suitable to elicit a T cell immune response in a host in need thereof, wherein the MHC class I T-cell epitopes originate from a plurality of antigens wherein the antigens comprise at least non-structural antigens and are from at least one flavivirus selected from the group of 10 Dengue virus (DENV), ZIKA virus (ZIKV) and Yellow Fever virus (YFV). The invention also relates to the polypeptides comprising polyepitopes of said antigens encoded by the recombinant polynucleotides.

The invention relates to the technical field of biology, and discloses a Zika virus non-structural protein 1 functional site and application thereof in design of a Zika virus attenuated strain. According to the invention, a new Zika virus virulence site is innovatively found, and a basis is provided for research of Zika virus and research and development work of related drugs. The invention also provides an attenuated mutant strain constructed on the basis of the virulence site, and the attenuated mutant strain has obvious attenuated characteristics and higher genetic stability, and can be used as an alternative strain of a Zika virus attenuated live vaccine.

The invention relates to the technical field of biological medicines, in particular to novel application of eltrombopag. The eltrombopag can act on an NS2B / NS3pro target spot, inhibit the activity of NS2B / NS3pro, inhibit the activity of dengue virus and Zika virus, can be applied to inhibition of the activity of flavivirus, and also has a treatment effect on diseases mediated by flavivirus.

The application provides a combined detection test strip for dengue virus, Zika virus antigen and antibody and a preparation method thereof; the combined detection test strip of the application adopts a multi-site recombinant antigen marking or multi-site recombinant antibody coating form for the combined detection test strip for dengue virus NS1 antigen and dengue virus IgG / IgM antibody, thereby improving the sensitivity of the reagent; the application also overcomes the problems of poor specificity and release residue of the latex microspheres by optimizing a blocking solution; color latex microspheres are used as the markers, the target is more intuitively detected according to the color of the lines, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is improved, dengue virus NS1, Zika virus NS1 antigen, dengue virus IgG / IgM antibody detection and Zika virus IgG / IgM antibody can be simultaneously detected; moreover, the application is convenient to carry and easy to operate, is convenient for on-site instant detection and can be used for large-scale preliminary screening.

The invention discloses a 3-site arylated derivative of indole as well as a synthesis method and application of the 3-site arylated derivative. 2-methylindole is used as a raw material and reacts with arylboronic acid after iodination, and a target compound is obtained. The method disclosed by the invention is simple in synthesis step and mild in reaction condition, and the C3-site arylated derivative of indole has an obvious inhibition effect on Zika virus and is expected to be used in potential antiviral drugs.

This invention relates to the field of pharmaceutical technology, disclosing a method for inhibiting Zika virus and its application. The invention identifies CD104 as the binding receptor for Zika virus and demonstrates that CD104 participates in Zika virus invasion of host cells, assisting in the virus's entry into host cells. Therefore, CD104 can provide a new and important target for the development of drugs that inhibit Zika virus invasion. Thus, this invention provides the application of a specific inhibitor of the Zika virus receptor CD104 protein in the preparation of drugs for the prevention or treatment of diseases caused by Zika virus infection.

The present disclosure relates to methods for inactivating Zika virus, which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation and a method for determining the residual formaldehyde content in a pharmaceutical composition containing inactivated viruses.

Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses (e.g., severe acute respiratory syndrome coronavirus [SARS-CoV], severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2, the virus and its mutant forms that cause COVID-19], Middle East respiratory syndrome coronavirus [MERS-CoV]), Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.

The invention provides an establishment method and application of a Zika virus infectious animal model, and belongs to the technical field of biology. According to the invention, ZIKV is inoculated to Toll-like receptor-deleted animals, such that the ZIKV challenging animal model is obtained. After the animal is inoculated with ZIKV, obvious ZIKV load can be detected in blood, liver, spleen, reproductive organ and brain tissue of the animal, moreover, the spleen is obviously swollen, the liver tissue has punctiform necrotic lesion, the splenosome is obviously reduced, and the mRNA level of inflammation related indexes Ccl5, Cxcl1, Isg15 and Isg56 is obviously up-regulated, which indicates that the ZIKV challenge model disclosed by the invention is successfully constructed; the method can be used in related researches such as ZIKV infection mechanism, vaccine research and development, anti-ZIKV drug research and development and the like.

The embodiment of the invention discloses a Zika virus DNA vaccine soluble microneedle and a preparation method thereof. The soluble microneedle comprises a base and a needle body, the needle body contains a shaping solution, and a preparation method of the shaping solution comprises the following steps: uniformly mixing a Zika virus DNA vaccine with the concentration of 4 mg / mL, deionized water and an adjuvant to obtain a mixed solution; and adding cane sugar and sodium hyaluronate into the mixed solution. The soluble microneedle for the Zika virus DNA vaccine has good mechanical strength, dissolving property and fixing effect, can effectively stimulate immune response of an organism, realizes efficient and convenient inoculation of the Zika virus DNA vaccine, provides calculation support for wide popularization and application of the Zika virus DNA vaccine, and has good practical application prospect.